María Luisa Limón - Concepedia

Author

María Luisa Limón

Hospital Universitario Virgen del Rocío ORCID

Also Known As

M. L. Limon, M. Limon, M. Limón, M. Luisa Limon, M. Luisa Limón, M. Mangas, M.L. Limon, M.L. Limón, Maria L. Limon, Maria Luisa Limon

Publications

1.4K

Citations

H-Index

Concepts

All Affiliations

Hospital Universitario Virgen del Rocío Hospital General Universitario Gregorio Marañón Hospital Universitario 12 De Octubre KU Leuven Istituto Oncologico Veneto

About

María Luisa Limón is an author at Hospital Universitario Virgen del Rocío specializing in oncology, medicine, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	17	681
2	Health Sciences	7	7	228
3	Public Health	1	1	27
4	Biostatistics	1	1	27
5	Cell Biology	1	1	18

María Luisa Limón

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer Thierry André, Elena Élez, Eric Van Cutsem, New England Journal of Medicine	2024	158
Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer Joan Albanell, Antonio González, Manuel Ruíz‐Borrego, Annals of Oncology	2011	120
Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial Thierry André, Elena Élez, Heinz‐Josef Lenz, The Lancet MedicineColorectal CancerPathologyImmune Checkpoint InhibitorIpilimumab Versus Nivolumab	2025	115
Durable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) Heinz‐Josef Lenz, Eric Van Cutsem, María Luisa Limón, Annals of Oncology Low-dose IpilimumabMedicineImmunologyColorectal CancerPathology	2018	92
MiR-107 and miR-99a-3p predict chemotherapy response in patients with advanced colorectal cancer Sonia Molina‐Pinelo, Amancio Carnero, Fernando Rivera, BMC Cancer	2014	75
Nivolumab plus low-dose ipilimumab as first-line therapy in microsatellite instability-high/DNA mismatch repair deficient metastatic colorectal cancer: Clinical update. Heinz‐Josef Lenz, Sara Lonardi, Vittorina Zagonel, Journal of Clinical Oncology Checkmate 142First-line TherapyImmunologyPathologyOncology	2020	60
Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial Fernando Rivera, Marta Izquierdo-Manuel, Pilar García‐Alfonso, European Journal of Cancer Surgical OncologyGastrointestinal OncologyGastro-oesophageal Junction AdenocarcinomaMedicinePerioperative Trastuzumab	2021	60
Surgery for metastases for esophageal-gastric cancer in the real world: Data from the AGAMENON national registry Alberto Carmona‐Bayonas, Paula Jiménez‐Fonseca, Isabel Echavarría, European Journal of Surgical Oncology Surgical OncologyEsophagusEsophageal CancerAgamenon National RegistryGastrointestinal Oncology	2018	59
Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): First results of the CheckMate 8HW study. Thierry André, Elena Élez, Eric Van Cutsem, Journal of Clinical Oncology ImmunologyPathologyPharmacotherapyVs ChemotherapyLogistic Analysis	2024	59
Nivolumab (NIVO) + low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Two-year clinical update. Heinz‐Josef Lenz, Sara Lonardi, Vittorina Zagonel, Journal of Clinical Oncology Checkmate 142ImmunologyPathologyMultimodalityPharmacotherapy	2020	43

Page 1